Five fractions of SBRT for prostate cancer

Affiliations

¹ Radiation Oncology, Fribourg Cantonal Hospital, Fribourg, Switzerland.
² Department of Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland.
³ Department of Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland; Faculty of Medicine, Geneva, Switzerland. Electronic address: thomas.zilli@eoc.ch.

Comment

Vérane Achard et al. Lancet Oncol. 2022 Dec.

. 2022 Dec;23(12):e530.

doi: 10.1016/S1470-2045(22)00615-5.

¹ Radiation Oncology, Fribourg Cantonal Hospital, Fribourg, Switzerland.
² Department of Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland.
³ Department of Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona 6500, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland; Faculty of Medicine, Geneva, Switzerland. Electronic address: thomas.zilli@eoc.ch.

No abstract available

Conflict of interest statement

We declare no competing interests.

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Tree AC, et al. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13. Lancet Oncol. 2022. PMID: 36113498 Clinical Trial.